NewYork-Presbyterian, in partnership with Weill Cornell Medicine and Columbia University, remains at the forefront of clinical research related to pulmonary hypertension. Our experts are responsible for some of the earliest genetic studies in the field along with ground-breaking clinical trials evaluating new medical treatments—including the first drug approved for pulmonary hypertension (intravenous epoprostenol) in 1995.
Heart Failure Research Institute
Advancing the understanding, prevention, and treatment of heart failure through research
Pulmonary Hypertension
Advancing Precision Medicine
Dr. Evelyn Horn and colleagues are recognized as leaders for their hemodynamic approach to complex pulmonary hypertension and right heart dysfunction, be it Group 1-5 or mixed group taxonomies. Our team has been part of the 7 center NIH study (PVDOMICS), applying extensive clinical phenotyping inclusive of multidimensional imaging, cutting-edge physiological testing in the cath lab, exercise testing, and precision medicine in the assessment of pulmonary vascular disease and right heart failure. We have the benefit of close collaboration with colleagues at the PVDOMICS sites, our expert CV imagers, and the Englander Institute for Precision Medicine. Explore our work below.
Our Research
Study highlights
Heterogeneity in Group 1 PH
Increasingly, Group 1 PAH with distinct CV and pulmonary phenotypes have been appreciated in current cohorts distinct from younger historic PAH. Current algorithms recommend more cautious use of PAH therapies in these groups due to potential worsening of LA hypertension in CV patients and worsened V/Q mismatch in chronic lung patients. In PVDOMICS we assessed them as Mixed Groups 1,2 and 1,3 with appropriate physiology beyond mere co-morbidities.
Aging and the cardiopulmonary system in pulmonary Vascular disease
Overlapping with above, markers of senescence are more likely to be associated with cardiovascular and pulmonary cohorts and as the world of senescence biology expands, likely to have meaningful expression here.
Metabolomics of RV dysfunction
RVF has a different metabolic expression and a better understanding of the peripheral expression of such vs gradients across the pulmonary circulation.
Hemodynamic monitoring in Cpc-PH with cardiomems
Increasingly our PH-HFpEF are getting cardiomems. As abnormal pulmonary capacitance is the pulsatile load contributing to RV failure and is dictated by SV/PA PP, aside from monitoring filling pressure trends, we can analyze effective pulmonary capacitance.
Atrial remodeling
Most of the focus re cardiac remodeling has been at the ventricular level but evidence suggests that RA for pulmonary hypertension and LA for PH-HFpEF & VHD, particularly with Cpc-PH may offer some of the hidden clue(s).
CTD and its expression in heart and lungs
What are we missing when we don’t look: 1) Paucity immune pathology ; 2) anti endothelial antibodies with similarities to antibody mediated rejection; 3) possible presence of complement mediated, interferon related pathways. Additionally, can we learn anything with use of microvascular assessment
